Profile data is unavailable for this security.
About the company
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
- Revenue in USD (TTM)7.77m
- Net income in USD-116.66m
- Incorporated2007
- Employees103.00
- LocationTonix Pharmaceuticals Holding Corp26 Main Street, Suite 101CHATHAM 07928United StatesUSA
- Phone+1 (212) 980-9155
- Fax+1 (212) 923-5700
- Websitehttps://www.tonixpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allied Corp | 21.51k | -9.00m | 16.18m | -- | -- | -- | -- | 752.43 | -0.0915 | -0.0915 | 0.0002 | -0.0711 | 0.0051 | 1.65 | 0.1441 | -- | -214.39 | -- | -- | -- | -6,919.57 | -- | -41,861.41 | -- | 0.0333 | -31.86 | -- | -- | -56.46 | -- | 31.30 | -- | -- | -- |
| Traws Pharma Inc | 226.00k | -18.16m | 16.26m | 16.00 | -- | 2.25 | -- | 71.94 | -0.8641 | -0.8641 | 0.0108 | 0.2853 | 0.0085 | -- | 12.91 | 14,125.00 | -68.21 | -63.43 | -104.99 | -85.72 | -- | -- | -8,033.63 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Aytu Biopharma Inc | 93.76m | -13.68m | 16.48m | 150.00 | -- | 0.5355 | -- | 0.1758 | -2.65 | -2.65 | 18.21 | 5.53 | 0.6792 | 2.42 | 2.93 | 625,053.30 | -9.91 | -33.56 | -25.58 | -52.81 | 65.32 | 56.89 | -14.60 | -73.81 | 0.6923 | 0.216 | 0.352 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 16.64m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Flora Growth Corp | 76.07m | -47.36m | 16.67m | 97.00 | -- | 1.81 | -- | 0.2191 | -6.62 | -7.97 | 10.04 | 0.7167 | 1.45 | 6.76 | 31.13 | 784,237.10 | -89.22 | -- | -130.91 | -- | 23.32 | -- | -61.35 | -- | 0.7897 | -- | 0.2317 | -- | 127.75 | -- | -1.87 | -- | -- | -- |
| Talis Biomedical Corp | 2.13m | -62.01m | 16.69m | 99.00 | -- | 0.2415 | -- | 7.82 | -34.26 | -34.26 | 1.18 | 37.93 | 0.0162 | -- | 11.92 | 21,555.55 | -46.98 | -68.18 | -51.14 | -74.22 | 98.08 | -- | -2,905.67 | -1,615.96 | -- | -- | 0.00 | -- | -55.65 | -2.24 | 45.13 | -- | -1.83 | -- |
| Galecto Inc | 0.00 | -30.83m | 17.08m | 13.00 | -- | 0.6066 | -- | -- | -1.15 | -1.15 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -63.50 | -48.46 | -78.33 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| Tonix Pharmaceuticals Holding Corp | 7.77m | -116.66m | 17.35m | 103.00 | -- | 0.1009 | -- | 2.23 | -8.62 | -8.62 | 0.4572 | 1.80 | 0.0409 | -- | -- | 75,417.48 | -61.38 | -59.46 | -68.01 | -65.92 | 38.97 | -- | -1,501.78 | -5,126.73 | 1.81 | -- | 0.0779 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Senti Biosciences Inc | 1.28m | -86.11m | 17.39m | 48.00 | -- | 0.3097 | -- | 13.64 | -1.93 | -1.44 | 0.0285 | 1.23 | 0.0097 | -- | 2.94 | 26,562.50 | -65.33 | -- | -71.42 | -- | -- | -- | -6,753.80 | -- | -- | -- | 0.0018 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -14.82m | 17.67m | 2.00 | -- | 0.5676 | -- | -- | -1.64 | -1.64 | 0.00 | 5.74 | 0.00 | -- | -- | 0.00 | -1.53 | -13.35 | -1.62 | -13.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1.81 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 4.91m | -13.32m | 17.70m | 20.00 | -- | -- | -- | 3.60 | -4.51 | -4.51 | 1.57 | -0.3033 | 0.2787 | -- | -- | 245,650.00 | -75.54 | -59.18 | -210.10 | -133.04 | -- | -- | -271.04 | -470.45 | -- | -- | 1.51 | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Minerva Neurosciences Inc | 0.00 | -31.60m | 17.96m | 9.00 | -- | -- | -- | -- | -4.48 | -4.48 | 0.00 | -5.23 | 0.00 | -- | -- | 0.00 | -61.90 | -49.89 | -65.32 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 17.07k | -8.38m | 18.11m | 7.00 | -- | 5.83 | -- | 1,061.22 | -0.7363 | -0.7363 | 0.0014 | 0.144 | 0.0032 | -- | 6.88 | 2,438.57 | -156.40 | -- | -211.46 | -- | -- | -- | -49,073.46 | -- | -- | -5.45 | 0.1122 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -37.28m | 18.12m | 35.00 | -- | 0.6267 | -- | 1,811.70 | -0.5791 | -0.5791 | 0.0002 | 0.4486 | 0.0002 | -- | 0.0581 | 285.71 | -72.29 | -43.60 | -81.84 | -47.82 | -- | -- | -372,767.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Biomx Inc | 0.00 | -26.17m | 18.23m | 58.00 | -- | 4.93 | -- | -- | -0.5433 | -0.5433 | 0.00 | 0.067 | 0.00 | -- | -- | 0.00 | -74.18 | -- | -101.74 | -- | -- | -- | -- | -- | -- | -21.95 | 0.7841 | -- | -- | -- | 7.59 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Tonix Pharmaceuticals Holding Corp's reporting currency: US Dollar USD
20.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2023 | 3.77m | 4.67% |
| Sabby Management LLCas of 31 Dec 2023 | 3.10m | 3.83% |
| Alyeska Investment Group LPas of 31 Dec 2023 | 2.70m | 3.34% |
| Marshall Wace LLPas of 31 Dec 2023 | 2.40m | 2.97% |
| Empery Asset Management LPas of 31 Dec 2023 | 2.31m | 2.86% |
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 900.90k | 1.12% |
| Altium Capital Management LPas of 31 Dec 2023 | 540.03k | 0.67% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 530.86k | 0.66% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 335.37k | 0.42% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 241.52k | 0.30% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
